Storage Time and DNA Quality Determine BRCA1/2 Sequencing Success in Prostate Cancer: A Multicentre Analysis with Therapeutic Implications

Background: Approximately 25.0% of metastatic prostate cancer patients harbour DNA damage repair mutations, including BRCA1 and BRCA2, which are actionable targets for poly(ADP-ribose) polymerase (PARP) inhibitors. Accurate detection of BRCA1/2 mutations is critical for guiding targeted therapies, b...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancers Jg. 17; H. 10; S. 1705
Hauptverfasser:	Vescovo, Mariavittoria, Raspollini, Maria Rosaria, Nibid, Lorenzo, Castiglione, Francesca, Nardi, Eleonora, de Biase, Dario, Massari, Francesco, Giunchi, Francesca, Pepe, Francesco, Troncone, Giancarlo, Malapelle, Umberto, Carosi, Mariantonia, Casini, Beatrice, Melucci, Elisa, Fassan, Matteo, Toffolatti, Luisa, Guerini-Rocco, Elena, Conversano, Federica, Rappa, Alessandra, Tommasi, Stefania, Coppola, Claudio Antonio, Zeppa, Pio, Caputo, Alessandro, Gaeta, Sara, Pagni, Fabio, Seminati, Davide, Vecchione, Andrea, Scarpino, Stefania, Righi, Daniela, Taffon, Chiara, Prata, Francesco, Perrone, Giuseppe
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	Switzerland MDPI AG 20.05.2025 MDPI
Schlagworte:	Biopsy BRCA1 protein BRCA2 protein Breast cancer Cancer Care and treatment Chi-square test DNA DNA damage DNA fragmentation DNA repair Genetic aspects Health aspects Metastases Metastasis Mutation Next-generation sequencing Poly(ADP-ribose) Poly(ADP-ribose) polymerase Prostate cancer Regression analysis Success Italy California United States > US BRCA1/2 NGS analysis metastatic castration resistant prostate cancer storage time target therapy
ISSN:	2072-6694, 2072-6694
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!